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Introduction
The recent Zika virus (ZIKV) epidemic in the Americas has 
focused attention on microcephaly as a major complication of 
in-utero infection and a cause of neurodisability in newborns1. 
Very little is known about the burden of microcephaly in 
Africa and, though ZIKV was first discovered in East Africa2 
and the Aedes mosquito vector for ZIKV is plentiful, it is not 
known whether ZIKV is a cause of microcephaly in the region. 
A cross-sectional survey in 1966-68 found high (52%) ZIKV 
antibody seroprevalence among children and adults in coastal 
Kenya3, though antibody cross-reactivity between ZIKV and 
other flaviviruses in circulation such as dengue virus (DENV) and 
West Nile virus (WNV) makes the interpretation of these 
data difficult. Several major flavivirus outbreaks have since 
occurred in the country4–6, with various serosurveys indicating 
ongoing flavivirus exposure7,8. Notably, high flavivirus antibody 
seroprevalence was reported amongst pregnant women sampled 
in 2002-03 in coastal Kenya but the association with birth 
outcomes was not determined9.
We previously initiated a perinatal and maternal health research 
programme in coastal Kenya to identify risk factors for: 
1) severe morbidity and mortality in mothers and newborns10 
and 2) preterm and small for gestational age (SGA) births in the 
INTERBIO-21st Study11. As part of these two studies, we took 
head circumference measurements and demographic and anthro-
pometric data allowing an estimation of: 1) the prevalence 
of microcephaly in coastal Kenya; 2) its association with 
maternal and newborn factors, and 3) its association with flavivi-
rus exposure.
Methods
Study population and data collection
This was a population-based, observational, cohort study 
undertaken at Kilifi County Hospital (KCH) between January 
2012 and October 2016. KCH is a rural public county hospital 
providing comprehensive obstetric care annually to approxi-
mately 5,000 women living along the Kenyan coast. All women 
completed a standardised admission record as part of two studies: 
an ongoing clinical surveillance study assessing risk factors 
for severe morbidity and mortality in mothers and newborns10 
and the INTERBIO-21st Study11. This included socio-demographic 
information, clinical history including antenatal clinic attend-
ance, clinical findings on admission, delivery details, and mater-
nal and newborn anthropometry. Gestational age was deter-
mined either by calculating the difference between the date of 
delivery and the date of the last reported menstrual period (LMP), 
including only births ≥37 weeks’ gestation (“LMP cohort”); or 
by a pregnancy dating ultrasound scan done ≤24 weeks’ gesta-
tion for a subset of participants enrolled in the INTERBIO-21st 
Study11, which included preterm and term births, referred to 
hereafter as the “scanned cohort”.
All newborns had anthropometric measurements (i.e. head 
circumference, weight and length) taken within 48 hours of birth 
by nurses and fieldworkers trained as part of the INTERBIO-21st 
Study, which included quarterly refresher training and continual 
quality control. Anthropometry for the scanned cohort was done 
in duplicate by two different fieldworkers, and discrepancies 
resolved by a third measurement.11 Maternal blood for routine 
and research samples was collected on admission, and umbilical 
cord blood was collected at delivery. Maternal and cord blood 
samples were processed, and plasma stored at -80ºC, within 
24 hours of collection. All mothers provided written informed 
consent for use of their biological samples and clinical data. 
The studies were approved by the Kenya Medical Research 
Institute (KEMRI) Scientific and Ethics Review Unit (KEMRI 
SERU # 3296 and 1778).
Laboratory procedures
Viral RNA detection. For qRT-PCR detection of ZIKV and 
other flaviviruses, viral RNA was isolated from cord plasma 
using the QIAamp® Viral RNA kit (Qiagen) according to 
manufacturer’s instructions. Samples were then screened for 
ZIKV and other flavivirus RNA using the QuantiFast RT-PCR 
kit (Qiagen) and published pan-flavivirus (Flavi allS, Flavi all 
AS2, Flavi all AS4 and Flavi all probe 3 mix)12 and ZIKV-specific 
primers and probes, Bonn E and Bonn NS113, on an ABI 
7500 Real Time PCR system. Sequences for all primers can be 
found in the indicated references. The PCR cycling conditions 
for the pan-flavivirus assay12 were: 50°C for 20 minutes, 95°C 
for 15 minutes, followed by 45 cycles comprising 95°C for 
15 seconds and 60°C for 1 minute. For ZIKV Bonn E and 
Bonn NS113 the conditions were: 50°C for 20 minutes, 95°C 
for 15 minutes, followed by 45 cycles comprising 95°C for 
15 seconds and 58°C for 1 minute. A cycle threshold value 
of <40 was used to define positives for all three assays. RNA 
isolated from ZIKV MR766 strain and a range of other 
flaviviruses (DENV, WNV and Yellow Fever virus) cultured 
in Vero E6 cells were used as positive controls, and the PCR 
mastermix without template used as a negative control in these 
assays.
FRNT90 assay. Cord plasma were screened for antibodies to 
ZIKV using a ZIKV focus reduction neutralisation test 
(FRNT90) and an in-house IgM ELISA assay against ZIKV NS1 
antigen strain MR766. For the FRNT90 assay, heat-inactivated 
cord plasma samples were diluted to 1:20 in 100 µl Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 10% fetal calf 
serum (D10), mixed with an equal volume of D10 containing 
approximately 100 focus-forming units of ZIKV MR766 strain, 
and incubated for 1 hour at 37ºC. The virus-plasma mixture 
was then overlaid onto 96-well flat-bottomed plates containing 
Vero E6 monolayers at 90% confluency for virus adsorption 
at 37ºC, 5% CO2 for 24 hours. The virus-plasma mixture was 
aspirated from the wells, 100 µl of D10 was added and the plates 
incubated for a further 24 hours at 37ºC, 5% CO2. Immunostain-
ing was then used to detect virus infection. Briefly, cells were 
gently washed with phosphate buffered saline (PBS), fixed in 4% 
paraformaldehyde in PBS for 10 minutes and permeabilized 
with permeabilization buffer (0.5% Triton X-100 in PBS) for 
30 minutes. The plates were blocked in Blocker Casein 
(ThermoFisher) before addition of 0.5 µg/ml of the anti- 
flavivirus E protein monoclonal antibody 4G2 (Native Antigen, 
UK, Cat. No AbFLAVENV-4G2) in permeabilization buffer 
for a 2-hour incubation at 37°C. Following a further series of 
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washes, plates were incubated with a 1:1000 dilution of horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgG 
antibody (Abcam, Cat. No. ab6789) in permeabilization 
buffer for 1 hour at 37°C, and colour development of foci done 
by addition of 3,3'-diaminobenzidine (Sigma) substrate for 
10 minutes at room temperature. The plates were finally washed, 
air dried and foci counted using an AID ELISpot reader. Plasma 
samples that resulted in at least 90% reduction in foci relative 
to wells incubated with virus only were considered flavivirus 
seropositive. Antibody titres against the ZIKV MR766 strain, 
and against a local DENV-2 isolate obtained from a patient in 
coastal Kenya, were then estimated for seropositive samples 
using the FRNT90 assay on twofold serial plasma dilutions. 
FRNT90 antibody titres were calculated using the Reed and 
Muench method14.
ZIKV NS1 IgM ELISA. For the IgM assay, 96-well flat- 
bottomed plates were first coated with 1 µg/ml of the ZIKV 
NS1 antigen (Native Antigen, UK, Cat. No. ZIKV-NS1) at room 
temperature overnight, then washed in wash buffer (0.05% 
Tween in PBS) and blocked with Blocker Casein (Ther-
moFisher) for 1 hour. Cord plasma were diluted 1:400 in Blocker 
Casein, added to plates in duplicate and incubated for 2 hours 
at room temperature. After a further series of washes, a 1:5000 
dilution of HRP-conjugated goat anti-human IgM antibody 
(KPL, Cat. No. 074-1003) in wash buffer was added to plates, 
incubated for 1 hour, washed and OPD substrate (Sigma) 
added for colour development for 15 minutes. Plates were read 
on a Biotek ELISA reader at a wavelength of 492 nm and optical 
density values for each sample acquired for analysis. Plasma 
from coastal Kenya residents with previous PCR-confirmed 
DENV infection15 were used as positive controls, while plasma 
from two European individuals and a pool of cord plasma from 
10 neonates without detectable responses to the ZIKV NS1 
antigen were used as negative controls. IgM ratios, defined 
as the ratio between mean sample OD and the mean OD of the 
negative controls, were then obtained and seropositivity defined 
as an IgM ratio of >3 as done by others16.
Statistical analysis
Based on World Health Organization recommendations14, 
microcephaly (cases) was defined as a birth head circumference 
(HC) Z score < -3 SD from the mean for gestational age and 
sex using INTERGROWTH-21st (IG21) newborn size reference 
charts for births <33 weeks’ gestation15, and standards for 
births ≥33 weeks’ gestation16. Controls were defined as newborns 
with HC Z scores between > -2 and ≤ 2 SD. Univariable 
logistic regression models were used to estimate associations 
between microcephaly and maternal or newborn variables 
hypothesised to be putative risk factors (22 variables tested; 
Table 1). A nominal two-sided p value was calculated as <0.002 
(i.e. 0.05 divided by 22 for the number of covariates) following 
Table 1. Association between maternal and newborn co-factors and microcephaly. The total number 
and prevalence of cases in the final case-control dataset, stratified by categories of neonatal and maternal 
variables, are shown. Data from the scanned and LMP cohorts are pooled in these analyses, but cohort-
specific frequencies are shown in Table 3. Crude odds ratios (OR), 95% confidence intervals (CI) and  
P values from univariable logistic regression models estimating associations with microcephaly with each 
variable in turn are shown. The reference population in each of the models is assigned a value of 1. The total 
number of newborns included in each analysis varies due to missing data for some variables. *Systolic or 
diastolic blood pressure >140 or >90 mmHg, respectively.
Covariate Categories n/N cases (%) Crude OR (95% CI) P value
Newborn factors 
Sex Male 69/4794 (1.4%) 1
Female 42/4303 (1.0%) 0.67 (0.46, 0.99) 0.05
Small for gestational age (SGA) Normal 61/7331 (0.8%) 1
SGA 50/1766 (2.8%) 3.47 (2.38, 5.07) <0.001
Type of birth Singleton 106/8879 (1.2%) 1
Multifetal 5/218 (2.3%) 1.9 (0.80, 4.75) 0.14
Year of birth 2012 17/1381 (1.2%) 1
2013 28/1499 (1.9%) 1.53 (0.83, 2.80) 0.17
2014 23/2379 (1.0%) 0.78 (0.42, 1.47) 0.45
2015 23/2043 (1.1%) 0.91 (0.49, 1.72) 0.78
2016 20/1795 (1.1%) 0.90 (0.47, 1.73) 0.76
Season January – March 24/2245 (1.1%) 1
April – June 41/2742 (1.5%) 1.40 (0.85, 2.33) 0.19
July – September 22/2240 (1.0%) 0.92 (0.51, 1.64) 0.77
October – December 24/1870 (1.3%) 1.20 (0.68, 2.13) 0.52
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Covariate Categories n/N cases (%) Crude OR (95% CI) P value
Maternal factors 
Sociodemographic factors 
Maternal age <20 years 17/1339 (1.3%) 1
20 to 35 years 87/6966 (1.2%) 0.98 (0.58, 1.66) 0.95
>35 years 7/783 (0.9%) 0.70 (0.29, 1.70) 0.43
Marital status Married 99/8329 (1.2%) 1
Unmarried 10/665 (1.5%) 1.27 (0.66, 2.44) 0.47
Education level Secondary or more 21/2627 (0.8%) 1
Primary school 73/5253 (1.4%) 1.75 (1.07, 2.85) 0.02
None 13/1010 (1.3) 1.62 (0.81, 3.24) 0.17
Residence Other 70/5893 (1.2%) 1
Kilifi township 41/3176 (1.3%) 1.09 (0.74, 1.60) 0.67
Type of house Stone wall 45/4702 (1.0%) 1
Mud wall 63/4328 (1.5%) 1.53 (1.04, 2.25) 0.03
Obstetric history
Parity Primigravida 41/3302 (1.2%) 1
Multigravida 70/5738 (1.2%) 0.98 (0.67, 1.45) 0.93
Antenatal care attendance ≥4 visits 69/5887 (1.2%) 1
0 to 3 visits 42/3434 (1.3%) 1.05 (0.72, 1.55) 0.79
Medication during pregnancy 
Folic acid supplements Yes 102/8292 (1.2%) 1
No 9/795 (1.1%) 0.92 (0.46, 1.82) 0.81
Malaria prophylaxis ≥3 doses 61/5166 (1.2%) 1
1 to 2 doses 47/3070 (1.5%) 1.30 (0.89, 1.91) 0.18
None 3/689 (0.4%) 0.37 (0.11, 1.17) 0.09
Tetanus vaccination Yes 95/7706 (1.2%) 1
No 13/1137 (1.1%) 0.93 (0.52, 1.66) 0.80
Maternal co-morbidities and infections 
Mid-upper arm circumference 
(MUAC) 
Normal (23–30cm) 76/6490 (1.2%) 1
Low (<23cm) 13/990 (1.3%) 1.12 (0.62, 2.03) 0.70
High (≥30cm) 9/997 (0.9%) 0.77 (0.38, 1.54) 0.46
Hypertension in pregnancy* No 92/7623(1.2%) 1
Yes 9/540 (1.7%) 1.39 (0.70, 2.77) 0.35
HIV status Negative 107/8605 (1.2%) 1
Positive 5/365 (1.1%) 0.88 (0.32, 2.40) 0.80
Maternal anaemia No 21/2321 (0.9%) 1
Yes 66/5436 (1.2%) 1.35 (0.82, 2.20) 0.24
VDRL (syphilis test) Negative 95/8014 (1.2%) 1
Positive 1/45 (2.2%) 1.89 (0.26, 13.89) 0.53
Other risk exposures 
Substance use No 108/8855 (1.2%) 1
Yes 3/232 (1.3%) 1.06 (0.33, 3.37) 0.92
Contact with cattle No 101/8225 (1.2%) 1
Yes 7/463 (1.5%) 1.23 (0.57, 2.67) 0.59
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Bonferroni adjustment for multiple testing. Variables reaching 
the nominal p<0.002 were then included in a multivariable 
logistic regression model and their adjusted association with 
microcephaly estimated. All logistic regression analyses were 
performed using pooled data from the scanned and LMP cohorts, 
respectively. To assess the distribution of variables between 
the two cohorts stratified analyses were performed using χ2 
tests (for categorical variables) and Mann-Whitney U-tests (for 
continuous variables). All analyses were carried out in Stata™ 
version 15 with two-sided p-values reported.
Results
Prevalence of microcephaly
Between January 2012 and October 2016 there were 21,143 
births at KCH. We excluded stillbirths (n=984), consent 
withdrawals (n=1771), births with missing key variables (sex, 
gestational age, HC Z scores and birth weight; n=3784) and 
preterm newborns for the LMP cohort only (n=3543). We included 
11061 live births in the main analysis (Figure 1). The mean 
gestational age of newborns in the scanned cohort was 38.6 weeks 
(95% CI 38.44, 38.66) and 39.3 weeks (95% CI 39.26, 39.32) for 
newborns in the LMP cohort.
There was an excess frequency of births with HC Z scores 
below -3 SD in the study population when compared to the 
expected normal distribution (Figure 2). However, the observed 
frequency of births with HC Z scores between -3 and <-2 SD was 
similar to the expected normal distribution (Figure 2).
A total of 16 (1.0%) of the 1529 newborns in the scanned 
cohort, and 198 (2.1%) of the 9532 newborns in the LMP cohort 
had a HC Z score <-3 SD. We hypothesised that the higher case 
Figure 1. Study participants flow diagram.
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Figure 2. Distribution of head circumference (HC) Z scores in the study population. The distribution of HC Z scores in the study population, 
measured as described in the Methods section, are shown. For comparison, the expected frequencies in a normal distribution are shown. 
For the LMP cohort distributions are shown for the full cohort, after exclusion of newborns with low birth weight (LBW; <2500 g), or for LBW 
newborns only. Distributions for the final analysis dataset (‘Pooled data [excluding LBW in LMP cohort]) are shown for comparison.
prevalence in the LMP cohort was due to the known inaccuracy 
of LMP in estimating gestational age as compared to ultrasound 
scans, leading to preterm births being classified as term, in turn 
resulting in a lower Z score than would have been assigned had 
the gestational age been known accurately14. Indeed, among 1399 
births (1253 term, 146 preterm) in the scanned cohort (used as 
gold standard) that also had corresponding LMP gestation ages, 
LMP gestation would have misclassified 9.3% (117/1253) of the 
term births as preterm births, and 39.7% (58/146) of preterms 
as term births. Therefore, to enhance the specificity of our case 
definition for associations, we excluded newborns with low birth 
weight (<2500 g, as per WHO guidelines) from the analysis 
of the LMP cohort. When this exclusion was applied the preva-
lence of microcephaly in the LMP cohort was 1.1% (95% 
CI 0.93, 1.39) among newborns weighing ≥2500 g (n=8333) 
and 8.6% (95% CI 7.13, 10.32) among those weighing 
<2500 g (n=1199), a difference that was statistically signifi-
cant (χ2=286.05, p<0.001; Fig. 2). In contrast, low birth weight 
showed no association with microcephaly in the scanned cohort 
(χ2=0.40, p=0.5). All further analyses on the LMP cohort were 
therefore restricted to newborns weighing ≥2500 g at birth, 
which when pooled with the scanned cohort gave a case prevalence 
of 1.1% (95% CI 0.93, 1.35).
Associations between microcephaly and maternal and 
newborn factors
To identify potential risk factors for microcephaly, we used a 
nested case-control approach whereby cases (n=111) were 
compared to controls (newborns with HC Z score > -2 and ≤ 
2 SD, n=8986) with respect to various maternal and newborn 
variables by logistic regression (Table 1 and Table 3). A strong 
association was observed between microcephaly and being 
born small for gestational age (SGA), defined as birth weight 
<10th centile for gestational age and sex on IG21 charts (OR=3.47, 
95% CI 2.38, 5.07, p<0.001). Maternal nutritional status, 
anaemia, HIV status, parity, receipt of interventions provided in 
the antenatal clinic and all other newborn and maternal factors 
tested showed no significant association with microcephaly.
Associations between microcephaly and flavivirus exposure
We used qRT-PCR and serological assays to investigate whether 
flavivirus exposure was associated with microcephaly in 
our dataset. To test for recent exposure to flavivirus, we 
measured IgM antibody responses against ZIKV NS1 antigen 
in cord plasma from 94 cases with available samples and 864 
controls matched by year of birth. Overall IgM seropositivity 
against ZIKV NS1 was 2.4% (95% CI 1.60, 3.59), though this 
was strongly confounded by cross-reactive responses to DENV 
since sera from 25 patients from coastal Kenya with lab- 
confirmed dengue infection17,18 were all seropositive on the ZIKV 
NS1 IgM assay. No association was evident between the ZIKV 
NS1 IgM response and microcephaly (Table 2). Furthermore, no 
ZIKV or other flavivirus RNA could be detected in cord 
plasma from the 94 cases or from a random selection of controls 
(n=471).
Of the 94 cases with samples available, 71 had sufficient cord 
plasma material for ZIKV FRNT90 assay. For the FRNT90 
assay, each of the 71 cases were matched to at least 10 controls 
by year of birth (n=755). The overall ZIKV FRNT90 antibody 
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Table 2. Associations between flavivirus serology and microcephaly. Prevalence of 
anti-ZIKV antibody responses as measured by FRNT90 assay and IgM ELISA is shown 
for cases and controls. Odds ratios, 95% confidence intervals and p value for the 
association with microcephaly are shown.
Seropositivity  
n/N (%) Crude OR (95% CI) P
ZIKV NS1 IgM assay
Controls 21/864 (2.4%) 1
Cases 2/94 (2.1%) 0.87 (0.20, 3.78) 0.86
ZIKV FRNT90 assay
Controls 61/755 (8.1%) 1
Cases 7/71 (9.7%) 1.24 (0.55, 2.83) 0.60
Table 3. Stratified analyses estimating associations between microcephaly and maternal and newborn 
co-factors in each cohort. Univariate analyses assessing the relationship between maternal and newborn 
factors and microcephaly in each cohort are shown. For each cohort the frequency of cases is shown, and χ2 
test used for all analyses. When all variables that were statistically significant at p<0.05 in any of the cohorts 
(indicated by *) were included in a multivariable logistic regression model, only SGA maintained an association 
with microcephaly (adjusted OR=3.41, 95% CI 2.30, 5.06, p<0.001).
LMP cohort Scanned cohort
Covariate Categories n/N cases (%) P value n/N cases (%) P value
A) Newborn factors




Female 37/3618 (1.0%) 5/685 (0.7%)




SGA 44/1481 (3.0%) 6/285 (2.1%)




Multifetal 3/193 (1.5%) 2/25 (8.0%)




2013 25/1225 (2.0%) 3/274 (1.1%)
2014 14/1712 (0.8%) 9/667 (1.3%)
2015 19/1621 (1.2%) 4/422 (0.9%)
2016 20/1795 (1.1%) No data




April - June 34/2379 (1.4%) 7/363 (1.9%)
July - September 17/1899 (0.9%) 5/341 (1.5%)
October - December 23/1552 (1.5%) 1/318 (0.3%)
B) Maternal factors 
Sociodemographic factors 
Maternal age <20 years 14/1164 (1.2%)
0.49
3/175 (1.7%)
0.5920 to 35 years 76/5835 (1.3%) 11/1131 (1.0%)
>35 years 5/659 (0.7%) 2/124 (1.6%)




Unmarried 6/575 (1.2%) 4/90 (4.4%)
Education level Secondary or more 20/2221 (0.9%)
0.22
1/406 (0.2%)
0.15Primary school 62/4443 (1.4%) 11/810 (1.4%)
None 10/832 (1.2%) 3/178 (1.7%)




Kilifi township 35/2346 (1.5%) 6/830 (0.7%)
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LMP cohort Scanned cohort
Covariate Categories n/N cases (%) P value n/N cases (%) P value




Mud wall 56/3708 (1.5%) 7/620 (1.1%)
Obstetric history 




Multigravida 56/4812 (1.2%) 14/926 (1.5%)
Antenatal care 




0 to 3 visits 38/3102 (1.2%) 4/203 (2.0%)
Medication during pregnancy 




No 9/713 (1.3%) 0/82 (0)
Malaria prophylaxis ≥3 doses 53/4106 (1.3%)
0.07
8/1060 (0.7%)
0.051 to 2 doses 40/2785 (1.4%) 7/285 (2.5%)
None 2/632 (0.3%) 1/57 (1.7%)




No 13/994 (1.3%) 0/143 (0)
Maternal co-morbidities and infections 
Mid-upper arm circumference 
(MUAC)
Normal (23-30cm) 65/5417 (1.2%)
0.85
11/1073 (1.0%)
0.22Low (<23cm) 9/822 (1.1%) 4/168 (2.4%)
High (≥30cm) 8/812 (1.0%) 1/185 (0.5%)




Yes 8/452 (1.8%) 1/88 (1.1%)




Positive 4/278 (1.4%) 0/87 (0)




Yes 56/4570 (1.2%) 10/866 (1.1%)




Positive 1/34 (2.9%) 0/11 (0)
Other risk exposures 




Yes 2/201 (1.0%) 1/31 (3.2%)




Yes 5/399 (1.2%) 2/64 (3.1%)
prevalence in the study population was 8.2% (95% CI 6.54, 
10.32), but this showed no association with microcephaly 
(Table 2 and Figure 3).
To characterise the ZIKV FRNT90 response further we measured 
FRNT90 antibody levels of the ZIKV FRNT90 seropositive cord 
plasma (7 cases, 61 controls) against a local DENV-2 isolate 
and compared these to the corresponding ZIKV FRNT90 titres. 
All ZIKV seropositive samples had antibody against DENV, 
with DENV FRNT90 titres for most samples (43 of the 68 ZIKV 
seropositive samples) being at least fourfold higher than the 
corresponding ZIKV FRNT90 titres (Figure 3). No sample had a 
ZIKV FRNT90 titre that was at least fourfold higher than that 
for DENV suggesting that the ZIKV response observed in our 
study population was largely due to cross-reactive responses 
to DENV or other related flaviviruses. Raw data used in these 
analyses are available as Underlying data19.
Discussion
This study set out to estimate the prevalence of microcephaly 
in coastal Kenya in a cohort of babies born in a rural public 
county hospital using data from two prospective studies that 
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Figure 3. DENV and ZIKV neutralising antibody titres in cord plasma. FRNT90 antibody titres measured against ZIKV MR766 strain in cord 
plasma from cases and controls are shown in (A), including p value from statistical comparison using the Mann-Whitney U test. For ZIKV 
FRNT90 seropositive samples (n=68) the corresponding FRNT90 antibody titres against a local DENV-2 isolate are shown in (B). The dashed 
line represents the assay limit of detection.
estimated gestational age clinically and using ultrasound, 
respectively. We then sought to identify risk factors for micro-
cephaly using a nested case-control design10. We found a preva-
lence of 1 to 2%, which given the 0.1% expected prevalence 
(<-3 SD in the reference populations) suggests a high, previ-
ously unrecognised, burden of microcephaly in this region. Using 
logistic regression we found that newborns with microcephaly 
were more likely to be born SGA. Finally, we did not detect any 
ZIKV or flavivirus RNA among cases or controls; nor differences in 
anti-ZIKV antibody responses between cases and controls.
A similarly high prevalence of microcephaly has been observed 
in Nigeria where approximately 1.9% of infants had a HC Z 
score <-3 SD20. In comparison, the average pre-ZIKV epidemic 
prevalence of microcephaly in 55 hospitals in the Americas 
was estimated at 0.04% (95% CI 0.041, 0.049)21, while the 
prevalence among 24 European Surveillance of Congeni-
tal Anomalies registries ranged between 0.004% and 0.04%22. 
During the ZIKV epidemic the overall microcephaly prevalence 
(HC Z score <-3 SD) in Pernambuco, one of the most severely 
affected states in Brazil, was estimated at 0.15% (95% CI 0.12, 
0.17)23, almost ten times lower than that observed in our dataset.
Definitions of microcephaly are complex and confounded by 
prematurity. Could we have overestimated the prevalence? We 
showed that use of the LMP led to an overestimate of gesta-
tional age compared with the gold-standard method of ultrasound 
scans in early pregnancy, which may have led to an overestimate 
in the prevalence of microcephaly. Furthermore, errors in meas-
uring head circumference could lead to misclassification. 
However, when we restricted analysis to the scanned cohort, in 
which gestational ages were calculated by high quality ultra-
sound scans in early pregnancy, and where two anthropometrists 
confirmed head circumferences, the prevalence of microcephaly 
remained high. Furthermore, even after restricting analysis in 
the LMP cohort to newborns with birth weight ≥2500 g, thus 
excluding all low birth weight (and hence most preterm births), 
the prevalence of microcephaly remained high.
We undertook detailed serological testing in cases and controls 
and did not find any ZIKV or flavivirus RNA. In addition, we 
showed no differences in anti-ZIKV FRNT90 or IgM antibody 
response between cases and controls. Notably, all the ZIKV 
FRNT90 seropositive samples were also seropositive for DENV. 
Comparison of FRNT90 titres is conventionally used to infer spe-
cific flavivirus exposure24; if the detected responses were due 
to recent ZIKV exposure we would expect ZIKV FRNT90 titres 
to be at least fourfold higher than the DENV FRNT90 titres in the 
corresponding sample(s)24. However, no sample had a ZIKV 
FRNT90 titre that was fourfold higher than the corresponding 
DENV FRNT90 titre. In fact, for more than half (63%) of the 
seropositive samples DENV FRNT90 titres were at least four-
fold higher than ZIKV FRNT90 titres. Furthermore, the lack of 
seasonality in the risk of microcephaly, lack of trend by 
calendar year, and absence of any difference by urban/rural 
residence suggest it is unlikely that a vector borne or respiratory 
infection, including ZIKV, is the cause of microcephaly in our 
setting. The only strongly significant risk factor for microceph-
aly in our population was SGA; this sub-group accounted for 
45% of all cases.
It is possible that we missed the viraemia in cord blood as a result 
of infection occurring earlier in pregnancy, as is common for 
ZIKV-associated microcephaly1,25. Sample collection in this study 
was only done at the time of delivery10. However, if ZIKV was a 
significant cause of microcephaly we would expect an increase 
in IgM levels to ZIKV in cord blood, as reported elsewhere 
among children with microcephaly secondary to ZIKV26–29. 
Furthermore, although molecular evidence of infection is not 
common among newborns with ZIKV-induced microcephaly, 
we would expect at least some to have prolonged ZIKV virae-
mia if this were a common cause. The complete absence of any 
molecular evidence of ZIKV in cases and controls, including 
in newborns with measurable cord blood anti-ZIKV FRNT90 
and IgM antibody responses, leads us to believe that the anti-ZIKV 
response detected in our study is cross-reactive to other flavi-
viruses. This hypothesis is supported by the high seroprevalence 
of DENV antibodies measured FRNT90 in this study and 
by other methods in previous studies in coastal Kenya7–9,30. Other 
potential infectious and non-infectious causes31,32, including 
genetic, nutritional and environmental factors, also warrant 
further investigation and may underlie the associations observed 
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between microcephaly and SGA newborns (as observed by 
others29).
In addition to using LMP in a subgroup to define gestational 
age, this study had other limitations. The study population only 
included births at KCH, and hence will have missed births 
occurring at home or in other local health facilities. However, 
we have important data from our uniquely detailed demographic 
surveillance system which indicates that approximately 40% of all 
births in the hospital catchment area occur at KCH.
This study has allowed the first estimation of the risk of 
congenital microcephaly in coastal Kenya. A 1-2% prevalence of 
microcephaly may impose a public health burden depending on 
the clinical outcomes associated. Future prospective studies to 
characterise and determine post-discharge mortality, neurocogni-




Harvard Dataverse: Replication Data for: Congenital Microcephaly 
Unrelated to Flavivirus Exposure in Coastal Kenya. https://doi.
org/10.7910/DVN/4EB9PG19.
This project contains the following underlying data:
•    microcephaly_dataverse_v1 (dataset containing demo-
graphic information, anthropometric measures and results 
of lab assays for participants included in the study).
•    GWarimwe_Microcephaly_Codebook (contains variable 
description and value labels).
Extended data
Harvard Dataverse: Replication Data for: Congenital Microcephaly 
Unrelated to Flavivirus Exposure in Coastal Kenya. https://doi.
org/10.7910/DVN/4EB9PG19.
This project contains the following extended data:
•    GWarimwe_Microcephaly_missing_data_summary 
(summary of missing data for analysed variables).
•    GWarimwe_Microcephaly_readme (readme file).
•    microcephaly_dataverse_final (STATA analysis code used 
for data analysis presented in this article).
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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